CanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials

Stock News

2025/07/16

CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1101741306"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101741306\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101741306?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101741306","market":"hk","top_or_hot":-1,"title":"CanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials","media":"Stock News","content":"<p>CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics (688185.SH) Secures NMPA Approval for Recombinant Trivalent Poliomyelitis Vaccine Clinical Trials\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-07-16 16:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688185","symbol_name":"康希諾","start_time":0,"source_url":"","article_id":"1101741306","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101741306","pubTimestamp":1752655645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","688185":"康希诺","BK0239":"医药制造","BK1576":"医药外包概念","03347":"泰格医药","BK1141":"生命科学工具和服务","BK1583":"高瓴概念"},"translate_title":"康希诺生物（688185.SH）重组三价脊髓灰质炎疫苗临床试验获NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"688185":1,"03347":1},"content_text":"CanSino Biologics (688185.SH) announced it has obtained clinical trial approval from China's National Medical Products Administration (NMPA) for its recombinant trivalent poliomyelitis vaccine (Sf-RVN cell). The regulatory clearance permits the company to initiate clinical studies evaluating the vaccine's efficacy in preventing poliomyelitis caused by type I, II, and III poliovirus infections. This milestone advances the company's innovative vaccine pipeline targeting preventable diseases with significant public health impact.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}